ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9085G>A (p.Ala3029Thr) (rs56179254)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001083149 SCV000073720 benign Hereditary breast and ovarian cancer syndrome 2020-12-07 criteria provided, single submitter clinical testing
Ambry Genetics RCV000129046 SCV000172960 benign Hereditary cancer-predisposing syndrome 2014-08-07 criteria provided, single submitter clinical testing This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000587355 SCV000210494 likely benign not provided 2020-09-04 criteria provided, single submitter clinical testing This variant is associated with the following publications: (PMID: 25682074, 18284688, 28678401, 28873162, 22228431, 20960228, 24884479, 19043619)
A.C.Camargo Cancer Center / LGBM, A.C.Camargo Cancer Center RCV000413118 SCV000492499 uncertain significance Breast neoplasm criteria provided, single submitter research
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000045707 SCV000600840 likely benign not specified 2017-04-20 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587355 SCV000695203 benign not provided 2017-07-27 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.9085G>A (p.Ala3029Thr) variant involves the alteration of a conserved nucleotide and results in a replacement of a small size and hydrophobic Alanine (A) with a medium size and polar Threonine (T). 5/5 in silico tools predict a damaging outcome for this substitution. This variant was found in 6/117622 control chromosomes at a frequency of 0.000051, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503). This variant has been reported in multiple breast and/or ovarian patients; however, without strong evidence for causality. BIC has reported co-occurrence of this variant with pathogenic BRCA1 variants c.5263_5264insC and c.66_67delAG, one in each of the three samples and UMD also reported the variant to co-occur with a BRCA2 splice-site variant c.7436-2A>G, one internally tested individual had a co-occurrence with BRCA1 c.5266dupC. These co-occurrence data strongly suggest the variant to be benign. In support a benign outcome, a likelihood ratio in favor of protein loss of function was calculated to be neutral (Karchin_2008). In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as benign/likely benign, including two laboratories have classified this variant as benign and likely benign, respectively, since last internal update. Taken together, this variant is classified as benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000587355 SCV000887957 benign not provided 2018-08-03 criteria provided, single submitter clinical testing
Color Health, Inc RCV000129046 SCV000902679 likely benign Hereditary cancer-predisposing syndrome 2015-09-09 criteria provided, single submitter clinical testing
Research and Development, ARUP Laboratories RCV001646887 SCV001852827 uncertain significance Breast-ovarian cancer, familial 2; Breast-ovarian cancer, familial 1; Hereditary breast and ovarian cancer syndrome 2020-01-20 criteria provided, single submitter curation
Breast Cancer Information Core (BIC) (BRCA2) RCV000114043 SCV000147531 uncertain significance Breast-ovarian cancer, familial 2 2002-05-29 no assertion criteria provided clinical testing
Sharing Clinical Reports Project (SCRP) RCV000114043 SCV000297574 benign Breast-ovarian cancer, familial 2 2008-10-02 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001353636 SCV000592253 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The BRCA2 p.Ala3029Thr variant was identified in 5 of 5332 proband chromosomes (frequency: 0.0009) from individuals or families with head and neck squamous cell carcinoma orbreast or ovarian cancer (Lee 2008, Laitman 2011, Wong-Brown 2015, Silva 2014, Chandrasekharappa 2017). The variant was identified in dbSNP (rs56179254) as “with other allele”, ClinVar (classified as benign by Invitae, Ambry Genetics, Integrated Genetics and 2 other submitters; as likely benign by Color, GeneDx, and two other submitters; and as uncertain significance by BIC and A.C.Camargo Cancer Center), LOVD 3.0 (observed 1x) and UMD-LSDB (observed 3x). The variant was identified in control databases in 18 of 249,750 chromosomes at a frequency of 0.00007 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Ashkenazi Jewish in 17 of 10,048 chromosomes (freq: 0.002, increasing the likelihood this could be a low frequency benign variant ) and European in 1 of 112,594 chromosomes (freq: 0.000009), while itwas not observed in the African, Latino, East Asian, Finnish, Other or South Asian populations. The variant was reported in UMD-LSDB as co-occurring with a pathogenic BRCA2 variant (c.7436-2A>G) and in BIC as co-occurring with pathogenic BRCA1 variants (p.Gln1756Profs*74 and p.Glu23Valfs*17). The p.Ala3029Thr residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.